Old Web
English
Sign In
Acemap
>
authorDetail
>
Amy Lauren Cummings
Amy Lauren Cummings
Medicine
Pathology
Oncology
Internal medicine
Pembrolizumab
4
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
P1.04-33 Deep Phenotyping of Immune Populations Reveals Baseline Predictors of Pembrolizumab Efficacy in NSCLC on KEYNOTE-001
2019
Journal of Thoracic Oncology
Philippe Rochigneux
Aaron Lisberg
Alejandro J. Garcia
Anne-Sophie Chrétien
S. Fattori
Anne Madroszyk
A Tseng
W. Akingbemi
Jaklin Gukasyan
John Madrigal
James Carroll
Zorawar S. Noor
Amy Lauren Cummings
Daniel Olive
Edward B. Garon
Show All
Source
Cite
Save
Citations (1)
P2.12-09 Phase 2 Study of Talazoparib Plus Low-Dose Temozolomide in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
2019
Journal of Thoracic Oncology
Amy Lauren Cummings
Jonathan H Goldman
Melody A. Mendenhall
D. Kanamori
A. Nguyen
Dong-Wan Kim
Zev A. Wainberg
Show All
Source
Cite
Save
Citations (1)
P1.12-22 A Phase 1b/2 Study of Niraparib Plus Temozolomide Versus Standard Care as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Patients
2019
Journal of Thoracic Oncology
Amy Lauren Cummings
Edward B. Garon
Zev A. Wainberg
Jonathan H Goldman
Show All
Source
Cite
Save
Citations (0)
MA 02.07 A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
2017
Journal of Thoracic Oncology
Aaron Lisberg
Jamie Hunt
N. Reese
T. Wang
P. Coluzzi
Marshall L. Spiegel
Krikor Bornazyan
James Carroll
John Madrigal
Blanca A Ledezma
Melody A. Mendenhall
J Bui
H.Lu
Amy Lauren Cummings
Z. Noor
Jonathan W. Goldman
Edward B. Garon
Show All
Source
Cite
Save
Citations (0)
1